series-a
Stage
1
Investors
About
RS Research develops smart nanomedicines for oncology using a proprietary Sagitta® polymer-drug conjugate platform to improve the therapeutic index of targeted chemotherapy and theranostics.
Explore RS Research's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.